Abacus Global Under Fire: Securities Fraud Probe Launched Over Inflated Life Expectancy Data

The Portnoy Law Firm has initiated a formal investigation into potential securities fraud at Abacus Global Management, Inc., signaling serious questions about the integrity of the company's financial reporting and valuation methodologies. The probe follows damaging allegations from Morpheus Research on June 4, 2025, which charged that Abacus used fraudulent life expectancy data to artificially inflate revenues, a revelation that sent the stock plummeting 21.5% to $6.00 per share and raised significant concerns about a $446 million life settlements portfolio.

The investigation represents a critical moment for the life insurance settlements industry, where actuarial accuracy and data integrity form the bedrock of company valuations and investor confidence. With the potential for class action litigation looming, Abacus Global ($ABACUS ticker pending verification) faces mounting legal and reputational risks that could fundamentally reshape its business model and market standing.

The Allegations: Fraud in Life Expectancy Modeling

According to Morpheus Research's June 2025 report, the core allegation centers on how Abacus Global sourced and utilized life expectancy data in its proprietary pricing tool—a critical component for valuing life settlement contracts. The specifics of the fraud allegation include:

• Reliance on Lapetus Solutions reports: Abacus allegedly depended heavily on life expectancy projections generated by Lapetus Solutions, a data provider whose estimates may have systematically overstated longevity assumptions
• Inflated revenue recognition: By using these elevated life expectancy figures, Abacus could justify higher valuations for life settlement contracts, artificially boosting reported revenues
• Avoided alternative data methods: The company allegedly failed to cross-reference or validate findings through alternative life expectancy collection and estimation methodologies, despite having access to such alternatives
• SEC disclosure violations: Most critically, Abacus's public filings with the Securities and Exchange Commission allegedly misrepresented the company's data sourcing practices and the reliability of its valuation framework

The $446 million in life settlements on Abacus's balance sheet now face serious valuation questions. If life expectancy assumptions were indeed inflated, the actual economic value of these contracts could be substantially lower than reported, potentially forcing significant write-downs and devastating shareholder equity.

Market Context: A Troubled Sector Under Scrutiny

The life insurance settlements market has attracted increasing regulatory and investor scrutiny in recent years. Life settlements—contracts where policyholders sell their life insurance policies to third parties in exchange for immediate cash—require precise actuarial analysis to price accurately. The margin for error is razor-thin: overestimate longevity and you overpay for contracts; underestimate it and you lose money as policyholders live longer than expected.

Industry challenges and competitive dynamics:

• Data integrity concerns: The sector relies on third-party data providers for mortality and longevity estimates, creating supply chain vulnerabilities
• Valuation opacity: Unlike equities or bonds, life settlement valuations lack transparent, standardized methodologies, making audits and comparisons difficult
• Regulatory heightened focus: The SEC and state insurance regulators have increased oversight of life settlement firms following past controversies
• Market size and stakes: The life settlements market represents hundreds of billions in notional value globally, making fraud in this space particularly consequential

Abacus Global's alleged misconduct is particularly damaging because it strikes at the transparency and reliability that investors demand. If a major player in this space cannot be trusted to accurately value its core asset class, confidence in the entire sector could erode.

Investor Implications: Capital at Risk

The investigation and stock decline carry severe implications for multiple stakeholder groups:

For equity shareholders: The 21.5% stock price decline to $6.00 already reflects significant value destruction, but further downside appears likely if litigation proceeds and damages are assessed. Shareholders could face:

• Dilution from settlement payouts
• Management turnover and operational disruption
• Loss of institutional investor confidence
• Potential delisting if the stock continues declining

For life settlement contract holders: If valuations are indeed overstated, the economic performance of these investments will underperform expectations, potentially creating civil liability exposure and regulatory sanctions.

For the broader market: A successful fraud prosecution at a material company in the life settlements space could trigger systematic repricing of life settlement assets across the industry, affecting multiple competitors and investment vehicles.

The litigation landscape: The Portnoy Law Firm's involvement signals that class action litigation is now a serious risk. Such suits typically seek to recover damages on behalf of investors who purchased Abacus Global shares during the period when the company allegedly made false representations about its data sourcing and valuation methodologies. Settlement costs, legal fees, and potential punitive damages could easily reach tens of millions of dollars.

Investors should monitor SEC filings for any voluntary disclosure or regulatory inquiry notices, as companies under investigation often must disclose material litigation risks to shareholders.

Looking Forward: Abacus's Uncertain Path

Abacus Global now faces a critical juncture. The company must navigate several simultaneous challenges: the pending investigation, potential class action litigation, possible SEC enforcement action, and operational disruptions from remediation efforts. Management's response—whether through early settlements, cooperation with regulators, or comprehensive internal reviews—will significantly impact the company's survival prospects.

For investors, the story serves as a cautionary reminder about due diligence in less-regulated, data-dependent sectors. Life settlements are not a commodity business; they require absolute confidence in the integrity of underlying valuations. When that confidence erodes, as it has for Abacus Global, recovery becomes extraordinarily difficult.

The coming months will be critical as the Portnoy Law Firm's investigation proceeds and regulatory authorities assess the full scope of the alleged misconduct. Until these matters resolve, the company faces severe headwinds in capital raising, institutional investment, and business development.